Information about GlobalPharmacyMeds.to
List of countries where we can ship Lurasidone:
Latest news releases on Lurasidone:
Lurasidone (/ lj ʊəˈr æ s ɪ d oʊ n /; trade name Latuda) is an atypical antipsychotic developed by Dainippon Sumitomo Pharma and marketed by Sunovion in the U.S.
Medscape - Schizophrenia and bipolar I depression dosing for Latuda (lurasidone), frequency-based adverse effects, comprehensive interactions, contraindications ...
Lurasidone: learn about side effects, dosage, special precautions, and more on MedlinePlus
Lurasidone is FDA approved for use in pediatric patients 10 years of age and older with bipolar I depression and adolescents 13 years and older with schizophrenia.
Il Lurasidone, nome commerciale LATUDA™, è un farmaco antipsicotico indicato, per il momento, nel trattamento della Schizofrenia .
New Atypical Antipsychotic Lurasidone Appears To Improve Schizophrenia Without Weight-Gain Side Effects
Latuda 18.5mg, 37mg and 74mg film-coated tablets - Summary of Product Characteristics (SmPC) by Sunovion Pharmaceuticals Europe Ltd
Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making
Latuda® is an atypical antipsychotic indicated for the treatment of depressive episode associated with bipolar depression in both adult and pediatric patients (10 to ...
Get information about Latuda® (lurasidone HCl) for the treatment of bipolar depression symptoms in adults and in children and teens (10-17 years).